Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

NCT07297797 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate Hypertension

Interventions

DRUG: HRS-9563 Injection
DRUG: sodium chloride injection

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.